Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by GrahamBon Sep 01, 2024 12:22pm
81 Views
Post# 36204675

RE:RE:RE:Financials anyone? Cash runway?

RE:RE:RE:Financials anyone? Cash runway?

Pandora wrote: From the Ascend presentation:

  • Ventripoint - The integration of Gen3Echo with Ventripoint’s innovative application of AI to echocardiography provides tremendous value to pediatric and adult echocardiographers in caring for their most complex patients. Ventripoint’s VMS product is powered by its proprietary KBR technology and provides accurate volumetric cardiac measurements with sMRI levels of accuracy. It can be used with all ultrasound systems supported by regulatory market approvals and is seamlessly integrated into the reading workflow enhancing diagnostic precision and treatment planning, ultimately improving the quality of pediatric care.



Interesting, but if they do not have cash, and they cannot close this financing how can they continue to promote and try to get any sales? This financing has been open and still could not fill and now they are going to retail investors. In the most recent financials, this is what they say, in addition to the numbers, I have posted. 


There is no certainty whether the Company will generate significant revenues or attain profitable operations in  the  near  future  and  there  can  be  no  assurance  that  it  will  achieve  profitability  in  the  future,  as  it  incurred  a  loss  of $2,608,879 and  had  a  negative  cash  flow  from  operating  activities  of  $1,974,232 for  the  six  months  ended June  30, 2024, and has accumulated $56,101,828 of losses as at June 30, 2024. The Company's ability to continue as a going concern is dependent on its ability to raise future capital, bringing its products to market and achieving and maintaining profitable operations. The outcome of these matters cannot be predicted at this time. As a result there exists a material uncertainty  which  creates  significant  doubt  regarding  the  Company’s  ability  to  continue  as  a  going  concern.  

<< Previous
Bullboard Posts
Next >>